Outgoing FDA Commissioner Scott Gottlieb chided drug developers and clinical research organizations for failing to take advantage of changes the agency has made to modernize the drug development and approval process and make it more efficient. "We appreciate that scientific and technical complexity is a real and ongoing challenge, but industry and academia also need to invest in and leverage these approaches and develop new incentives that reward collaboration and data sharing across the clinical research enterprise," Gottlieb said.
Gottlieb: Drug R&D slow to act on FDA modernization efforts
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.